Abbott Laboratories (ABT) Income Statement
ABT 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsABT revenue and net income
Where ABT's revenue goes
2025Each bar shows an amount and its share of revenue. ABT kept 14.7% of revenue as net income.
ABT profit margins
ABT growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +5.7% | +0.5% | +5.1% | +8.1% |
| Gross profit | +15.4% | +3.3% | +7.2% | +8.4% |
| Operating income | +17.9% | −1.3% | +8.8% | +10.6% |
| Net income | −51.3% | −2.0% | +7.7% | +4.0% |
| EPS (diluted) | +10.3% | −1.2% | +7.1% | +9.1% |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
ABT quarterly EPS vs estimates
Abbott beat the analyst EPS estimate in 8 of the last 8 quarters. Next report: October 21, 2026 (estimate $1.42).
ABT income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $44.33B | $41.95B | $40.11B | $43.65B | $43.08B | $34.61B | $31.90B | $30.58B | $27.39B | $20.85B |
| Cost of revenue | $19.72B | $20.62B | $20.07B | $21.33B | $19.86B | $17.23B | $15.21B | $14.76B | $14.32B | $9.61B |
| Gross profit | $24.61B | $21.32B | $20.04B | $22.32B | $23.21B | $17.38B | $16.69B | $15.82B | $13.07B | $11.24B |
| Research & development | $2.96B | $2.82B | $2.72B | $2.85B | $2.74B | $2.42B | $2.41B | $2.29B | $2.13B | $1.36B |
| Sales, general & admin | $12.38B | $11.70B | $11.20B | $11.01B | $11.32B | $9.70B | $9.77B | $9.74B | $9.12B | $6.67B |
| Total operating expenses | $16.59B | $14.47B | $13.60B | $13.96B | $14.01B | $12.09B | $12.10B | $11.98B | $11.09B | $8.00B |
| Operating income | $8.05B | $6.83B | $6.43B | $8.36B | $9.20B | $5.29B | $4.59B | $3.84B | $1.97B | $3.25B |
| Interest income | $135.0M | $344.0M | $384.0M | $377.0M | $491.0M | $492.0M | $94.0M | $105.0M | $124.0M | $99.0M |
| Interest expense | $341.0M | $603.0M | $698.0M | $315.0M | $410.0M | $708.0M | $818.0M | $729.0M | $880.0M | $304.0M |
| Income before taxes | $8.47B | $7.01B | $6.66B | $8.31B | $8.21B | $4.97B | $4.08B | $2.87B | $2.23B | $1.41B |
| Income taxes | $1.94B | −$6.39B | $941.0M | $1.37B | $1.14B | $497.0M | $390.0M | $539.0M | $1.88B | $350.0M |
| Net income | $6.52B | $13.40B | $5.72B | $6.93B | $7.07B | $4.50B | $3.69B | $2.37B | $477.0M | $1.40B |
| EBITDA | $11.92B | $10.83B | $10.61B | $11.89B | $12.16B | $9.00B | $7.91B | $6.88B | $6.13B | $3.07B |
| EPS (diluted) | $5.15 | $4.67 | $4.44 | $5.34 | $5.21 | $3.65 | $3.24 | $2.88 | $2.50 | $2.20 |
| Gross margin | 55.5% | 50.8% | 50.0% | 51.1% | 53.9% | 50.2% | 52.3% | 51.7% | 47.7% | 53.9% |
| Operating margin | 18.2% | 16.3% | 16.0% | 19.2% | 21.4% | 15.3% | 14.4% | 12.6% | 7.2% | 15.6% |
| Net margin | 14.7% | 31.9% | 14.3% | 15.9% | 16.4% | 13.0% | 11.6% | 7.7% | 1.7% | 6.7% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $12.59B | $11.16B | $11.46B | $11.37B | $11.14B | $10.36B | $10.97B | $10.63B | $10.38B | $9.96B | $10.24B | $10.14B |
| Cost of revenue | $5.29B | $4.88B | $4.92B | $5.03B | $4.85B | $4.91B | $5.38B | $5.21B | $5.07B | $4.94B | $4.98B | $5.11B |
| Gross profit | $7.30B | $6.28B | $6.54B | $6.34B | $6.29B | $5.44B | $5.60B | $5.43B | $5.30B | $5.02B | $5.26B | $5.03B |
| Research & development | $882.0M | $756.0M | $735.0M | $785.0M | $732.0M | $703.0M | $728.0M | $713.0M | $697.0M | $683.0M | $690.0M | $661.0M |
| Sales, general & admin | — | $3.74B | $3.13B | $3.05B | $3.09B | $3.06B | $2.91B | $2.90B | $2.94B | $2.96B | $2.72B | $2.68B |
| Total operating expenses | $5.52B | $4.44B | $4.29B | $4.31B | $4.24B | $3.76B | $3.61B | $3.61B | $3.62B | $3.64B | $3.39B | $3.36B |
| Operating income | $1.78B | $1.84B | $2.25B | $2.06B | $2.05B | $1.69B | $1.99B | $1.82B | $1.69B | $1.39B | $1.86B | $1.68B |
| Interest income | — | $106.0M | $27.0M | $77.0M | $39.0M | $82.0M | $91.0M | $91.0M | $82.0M | $80.0M | $89.0M | $59.0M |
| Interest expense | $299.0M | $174.0M | $120.0M | $44.0M | $121.0M | $134.0M | $152.0M | $166.0M | $168.0M | $117.0M | $235.0M | $148.0M |
| Income before taxes | $1.52B | $1.45B | $2.36B | $2.18B | $2.15B | $1.78B | $2.03B | $1.94B | $1.61B | $1.44B | $1.79B | $1.67B |
| Income taxes | $596.0M | $372.0M | $582.0M | $536.0M | $371.0M | $453.0M | −$7.20B | $294.0M | $305.0M | $211.0M | $201.0M | $235.0M |
| Net income | $928.0M | $1.08B | $1.78B | $1.64B | $1.78B | $1.32B | $9.23B | $1.65B | $1.30B | $1.23B | $1.59B | $1.44B |
| EBITDA | $2.79B | $2.25B | $3.19B | $3.09B | $3.05B | $2.67B | $2.99B | $2.91B | $2.58B | $2.36B | $2.84B | $2.64B |
| EPS (diluted) | $1.31 | $1.15 | $1.50 | $1.30 | $1.26 | $1.09 | $1.34 | $1.21 | $1.14 | $0.98 | $1.19 | $1.14 |
| Gross margin | 58.0% | 56.3% | 57.0% | 55.7% | 56.4% | 52.6% | 51.0% | 51.0% | 51.1% | 50.4% | 51.3% | 49.6% |
| Operating margin | 14.2% | 16.5% | 19.6% | 18.1% | 18.4% | 16.3% | 18.1% | 17.1% | 16.2% | 13.9% | 18.2% | 16.5% |
| Net margin | 7.4% | 9.6% | 15.5% | 14.5% | 16.0% | 12.8% | 84.1% | 15.5% | 12.5% | 12.3% | 15.6% | 14.2% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in ABT's financial statements (latest annual report filed February 20, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
ABT financial results
In fiscal year 2025 (ended December 31, 2025), Abbott reported revenue of $44.3 billion, up 5.7% from the year before. It had net income of $6.5 billion (down 51.3%), a net profit margin of 14.7%. Diluted earnings per share came to $5.15. Over five years revenue grew at an average rate of 5.1% a year.
See the ABT stock overview for the latest quote and news, or the ABT chart for price history and technical indicators.
ABT income statement FAQ
What is Abbott's annual revenue?
Abbott reported total revenue of $44.3 billion for fiscal year 2025, which ended on December 31, 2025. That was up 5.7% from $42.0 billion the previous year.
Is Abbott profitable?
Yes. Abbott reported net income of $6.5 billion in fiscal 2025, a net profit margin of 14.7%; its operating margin was 18.2%.
What is Abbott's gross margin?
Abbott's gross margin was 55.5% in fiscal 2025: for every $100 of revenue, Abbott kept $56 after the direct cost of its products and services.
How much does Abbott spend on research and development?
Abbott spent $3.0 billion on research and development in fiscal 2025, 6.7% of revenue.
How fast is Abbott growing?
Revenue grew 5.1% a year on average over the last five fiscal years, from $34.6 billion to $44.3 billion.
What are Abbott's earnings per share?
Abbott earned $5.15 per diluted share in fiscal 2025, compared with $4.67 a year earlier.
When will Abbott report its next earnings?
Abbott is expected to report results for the quarter ending September 30, 2026 on October 21, 2026 before the market opens.
When does Abbott's fiscal year end?
Abbott's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on February 20, 2026.